Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: " A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain | BMC Psychiatry BioMed Central Research article Open Access A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit hyperactivity disorder in Spain Jihyung Hong 1 2 Tatiana Dilla3 and Jorge Arellano2 Address 1LSE Health London School of Economics London UK 2Eli Lilly and Company Windlesham UK and 3Eli Lilly and Company S.A Alcobendas Madrid Spain Email Jihyung Hong - j.hong@lse.ac.uk Tatiana Dilla - dilla_tatiana@lilly.com Jorge Arellano - arellano_jorge@lilly.com Corresponding author Published 14 April 2009 Received 30 August 2008 BMC Psychiatry 2009 9 15 doi 10.1186 1471-244X-9-15 Accepted I4 April 2009 This article is available from http www.biomedcentral.cOm 1471-244X 9 15 2009 Hong et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Attention Deficit Hyperactivity Disorder ADHD is a neurobehavioural disorder affecting 3-6 of school age children and adolescents in Spain. Methylphenidate MPH a mild stimulant had long been the only approved medication available for ADHD children in Spain. Atomoxetine is a non-stimulant alternative in the treatment of ADHD with once-a-day oral dosing. This study aims to estimate the cost-effectiveness of atomoxetine compared to MPH. In addition atomoxetine is compared to no medication for patient populations who are ineligible for MPH i.e. having stimulant-failure experience or co-morbidities precluding stimulant medication . Methods An economic model with Markov processes was developed to estimate the costs and benefits of atomoxetine versus either MPH or no medication . The incremental cost per quality-adjusted life-year QALY was calculated for atomoxetine relative to the comparators. The Markov .